180 Life Sciences Corp (FRMM)
Drugs • Health Care
May 15, 2026 180 Life Sciences Corp. Reports Transformative Q1 2026 Financial Results 180 Life Sciences Corp. reported a transformative Q1 2026 with $2.9 million in revenue, marking a significant shift towards digital assets. Despite a net loss of $76.26 million, the company shows strong growth in assets and cash flow as it navigates market challenges and regulatory uncertainties.
April 01, 2026 180 Life Sciences Corp 2025 Annual Report: A Transformative Year in Digital Assets The 2025 annual report of 180 Life Sciences Corp reveals a significant rebranding to ETHZilla Corporation, focusing on digital assets. Despite reporting $6.5 million in revenue, the company faced a net loss of $450.5 million due to strategic shifts and increased expenses. Key acquisitions and a pivot towards staking and tokenization highlight its future direction.
December 30, 2025 ETHZilla Corporation Faces Scrutiny Amid Fraud Investigation ETHZilla Corporation is under investigation by the Schall Law Firm for potential securities law violations following its recent financial maneuvers. The company's stock dropped 8.7% amid concerns over transparency, prompting shareholders to explore their legal options.
November 14, 2025 180 Life Sciences Corp. Reports Q3 2025 Financial Results: A Strategic Shift in Focus ETHZilla Corporation, formerly 180 Life Sciences, reports a net loss of $216.7 million for Q3 2025 as it shifts focus to blockchain and decentralized finance. The company is undergoing significant restructuring, including a reverse stock split and leadership changes, while pursuing new revenue streams through Ethereum-focused strategies.
July 23, 2025 180 Life Sciences Corp. Reports Q2 2025 Financial Results: A Shift Towards iGaming 180 Life Sciences Corp. reported a net loss of $1.7 million in Q2 2025 as it shifts focus from biotechnology to the iGaming sector. The company's acquisition of a Gaming Technology Platform marks a strategic pivot, despite increased operational losses and the need for further capital.
May 15, 2025 180 Life Sciences Corp. Reports Q1 2025: Financial Performance and Strategic Shifts 180 Life Sciences Corp. has reported its Q1 2025 financial results, showcasing a strategic pivot towards the iGaming industry. Despite a net loss increase, the company is investing in online gaming while managing its legacy biotechnology programs amidst liquidity challenges.
March 31, 2025 180 Life Sciences Corp Reports 2024 Annual Financial Results 180 Life Sciences Corp's 2024 annual report reveals a significant reduction in losses and improved cash management, despite ongoing financial challenges. The company is shifting focus towards iGaming and its Gaming Technology Platform while addressing the need for additional capital.
February 21, 2025 SWOT Analysis of 180 Life Sciences Corp in 2025 This SWOT analysis examines 180 Life Sciences Corp's strengths in anti-inflammatory therapeutics, weaknesses related to financial viability, and opportunities for market expansion. It also addresses threats from competition and regulatory challenges, emphasizing the need for strategic management.
November 14, 2024 180 Life Sciences Corp. Q3 2024 Financial Report: A Shift from Biotech to iGaming 180 Life Sciences Corp. has shifted focus from biotechnology to online gaming, reporting Q3 2024 net losses of $836,700. The company's strategic acquisition of a blockchain gaming platform aims to capitalize on the growing iGaming market, despite facing liquidity and regulatory challenges.
August 12, 2024 180 Life Sciences Corp. Reports Strong Q2 2024 Performance 180 Life Sciences Corp. reported a strong Q2 2024, achieving a net income of $11,781, a major turnaround from last year's losses. Key factors include significant insurance proceeds and reduced expenses, reflecting the company's focused strategy amidst ongoing challenges.
May 15, 2024 180 Life Sciences Corp. Reports Q1 2024 Financial Performance: A Glimpse into Recovery 180 Life Sciences Corp. reports a significant reduction in net loss for Q1 2024, highlighting improved operational efficiencies and strategic expense management. Despite liquidity challenges and a negative equity position, the company is taking proactive steps to enhance compliance and shareholder value.
March 25, 2024 180 Life Sciences Corp. Reports Financial Results for 2023: A Year of Transformation and Challenges 180 Life Sciences Corp. reports significant reductions in losses for 2023, with a net loss of $19.93 million. The company navigated financial challenges through operational efficiency and strategic financing while preparing for future growth amidst legal hurdles.